Status:
UNKNOWN
Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification
Lead Sponsor:
Peking University
Conditions:
Esophageal Squamous Cell Carcinoma
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
This is a phase 2 trial investigating the effect and safety of afatinib plus toripalimab in previously treated recurrent or metastasic esophageal squamous cell carcinoma with EGFR overexpression or EG...
Eligibility Criteria
Inclusion
- Having signed informed consent.
- Age 18 to 70 years old.
- Histologically confirmed esophageal squamous carcinoma
- Immunohistochemistry confirmed EGFR(3+) or EGFR-FISH-amplification or next generation sequencing confirmed EGFR-amplification.
- Computed tomography (CT) or magnetic resonance imaging (MRI) confirmed unresectable metastasic or recurrent ESCC.
- Refractory or intolerant to at least one regimen.
- Measurable disease according to the Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria(diameter of the lesion should be more than 10mm by spiral CT or MRI, more than 20mm by common CT, the date of image should be less than 21 days before enrollment)
- Life expectancy of ≥3 month
- Eastern Cooperative Oncology Group (ECOG) 0-2
- WBC\>3,000/mm3, absolute neutrophil count ≥1500/mm3, platelet\>100,000/mm3, Hb\>9g/dl，Bilirubin level \< 1.5 times ULN，Serum creatinine \<1.5 times ULN，ALT and AST\<2.5 times ULN ，AKP \< 2.5 times ULN ，(≤5 times ULN in patients with liver metastases)(within 7 days before enrollment)
- No sever complication, such as active gastrointestinal bleeding, perforation, jaundice, obstruction, non-cancerous fever\>38℃.
- Good compliance
Exclusion
- Currently receiving other effective regimens.
- Previous anticipate other clinical trial within 4 weeks before entering this study.
- No measurable lesions, eg. pleural fluid and ascites.
- With other malignancy within 5 year, except non-melanoma skin cancer and cervical carcinoma in situ.
- Heart failure or other sever organ dysfunction, eg. coronary artery disease, myocardial infarction within the last 6 months.
- Mentally abnormal or disable cognition,including central nervous system (CNS) metastasis.
- HIV infection, active hepatitis B or hepatitis C.
- Unstable systemic diseases such as poorly controlled diabetes.
- Interstitial lung disease, such as interstitial pneumonia, pulmonary fibrosis, or evidence of interstitial lung disease showed in X-ray/CT.
- Keratitis, ulcerative keratitis or severe dry eye syndrome. Known hypersensitivity to study drug.
- Pregnancy or lactation period.
- Active severe infection within 14 days
- Contraindications of afatinib.
- Pregnancy (determined by serum β-chorionic gonadotropin test) or breast-feeding
- Gastrointestinal perforation and/or fistula occurred within 3 months before enrollment
- Patients with active autoimmune disease or stable disease with high risk of recurrence
- Use corticosteroids (dose of prednisone or similar drugs\> 10mg/day) or other immunosuppressive agents within 14 days before enrollment
- Live vaccine was injected within 4 weeks before enrollment
- Previously received treatment with EFFR-TKI
Key Trial Info
Start Date :
July 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2023
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT04880811
Start Date
July 1 2021
End Date
May 1 2023
Last Update
July 13 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Cancer Hospital and Institute
Beijing, Beijing Municipality, China, 100142